190 related articles for article (PubMed ID: 32586143)
1. On-treatment HDL cholesterol predicts incident atrial fibrillation in hypertensive patients with left ventricular hypertrophy.
Okin PM; Hille DA; Wachtell K; Kjeldsen SE; Julius S; Devereux RB
Blood Press; 2020 Oct; 29(5):319-326. PubMed ID: 32586143
[No Abstract] [Full Text] [Related]
2. In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study.
Okin PM; Hille DA; Wiik BP; Kjeldsen SE; Lindholm LH; Dahlöf B; Devereux RB
Diabet Med; 2013 Oct; 30(10):1189-97. PubMed ID: 23587029
[TBL] [Abstract][Full Text] [Related]
3. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
[TBL] [Abstract][Full Text] [Related]
4. Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients.
Okin PM; Hille DA; Larstorp AC; Wachtell K; Kjeldsen SE; Dahlöf B; Devereux RB
Hypertension; 2015 Aug; 66(2):368-73. PubMed ID: 26056336
[TBL] [Abstract][Full Text] [Related]
5. Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation.
Okin PM; Hille DA; Wachtell K; Kjeldsen SE; Boman K; Dahlöf B; Devereux RB
J Hypertens; 2015 Jul; 33(7):1480-6. PubMed ID: 25799208
[TBL] [Abstract][Full Text] [Related]
6. Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study.
Ariansen I; Reims HM; Gjesdal K; Olsen MH; Ibsen H; Devereux RB; Okin PM; Kjeldsen SE; Dahlöf B; Wachtell K
Blood Press; 2012 Feb; 21(1):6-11. PubMed ID: 22070095
[TBL] [Abstract][Full Text] [Related]
7. Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy.
Okin PM; Kamel H; Kjeldsen SE; Devereux RB
J Hypertens; 2016 Sep; 34(9):1831-7. PubMed ID: 27254312
[TBL] [Abstract][Full Text] [Related]
8. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
Olsen MH; Wachtell K; Beevers G; Dahlöf B; de Simone G; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Lyle PA; Nieminen MS; Omvik P; Oparil S; Wedel H
J Hypertens; 2009 Mar; 27(3):567-74. PubMed ID: 19262226
[TBL] [Abstract][Full Text] [Related]
9. Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy.
Okin PM; Bang CN; Wachtell K; Hille DA; Kjeldsen SE; Dahlöf B; Devereux RB
Circ Arrhythm Electrophysiol; 2013 Apr; 6(2):243-51. PubMed ID: 23403268
[TBL] [Abstract][Full Text] [Related]
10. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Wachtell K; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Nieminen MS; Olsen MH; Okin PM; Palmieri V; Rokkedal JE; Devereux RB
Blood Press; 2010 Jun; 19(3):169-75. PubMed ID: 20438307
[TBL] [Abstract][Full Text] [Related]
11. Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study.
Bang CN; Okin PM; Køber L; Wachtell K; Gottlieb AB; Devereux RB
J Hypertens; 2014 Mar; 32(3):667-72. PubMed ID: 24379001
[TBL] [Abstract][Full Text] [Related]
12. Racial differences in incident atrial fibrillation among hypertensive patients during antihypertensive therapy.
Okin PM; Bang CN; Wachtell K; Hille DA; Kjeldsen SE; Julius S; Dahlöf B; Devereux RB
Am J Hypertens; 2014 Jul; 27(7):966-72. PubMed ID: 24552888
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
[TBL] [Abstract][Full Text] [Related]
14. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
Okin PM; Wachtell K; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Julius S; Lindholm LH; Nieminen MS; Edelman JM; Hille DA; Dahlöf B
JAMA; 2006 Sep; 296(10):1242-8. PubMed ID: 16968848
[TBL] [Abstract][Full Text] [Related]
15. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy.
Okin PM; Kjeldsen SE; Julius S; Hille DA; Dahlöf B; Edelman JM; Devereux RB
Eur Heart J; 2010 Sep; 31(18):2271-9. PubMed ID: 20601389
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
[TBL] [Abstract][Full Text] [Related]
17. Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study.
Larstorp AC; Ariansen I; Gjesdal K; Olsen MH; Ibsen H; Devereux RB; Okin PM; Dahlöf B; Kjeldsen SE; Wachtell K
Hypertension; 2012 Aug; 60(2):347-53. PubMed ID: 22753219
[TBL] [Abstract][Full Text] [Related]
18. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Dahlöf B;
Ann Intern Med; 2007 Sep; 147(5):311-9. PubMed ID: 17785486
[TBL] [Abstract][Full Text] [Related]
19. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
Gerdts E; Wachtell K; Omvik P; Otterstad JE; Oikarinen L; Boman K; Dahlöf B; Devereux RB
Hypertension; 2007 Feb; 49(2):311-6. PubMed ID: 17178978
[TBL] [Abstract][Full Text] [Related]
20. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
Kizer JR; Dahlöf B; Kjeldsen SE; Julius S; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Wachtell K; Edelman JM; Snapinn SM; Harris KE; Devereux RB
Hypertension; 2005 Jan; 45(1):46-52. PubMed ID: 15583076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
